Suspension of trading
Valuation Decoy Therapeutics Inc. Börse Stuttgart
Stocks
FP11
US79400X6022
Biotechnology & Medical Research
|
Delayed
Börse Stuttgart
11:48:59 2024-06-14 EDT
|
5-day change | 1st Jan Change | ||
| 3.104 EUR | -3.96% |
|
+704.15% | +435.17% |
Company Valuation: Decoy Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 21.65 | 22.39 | 3.485 | 2.56 | 2.652 | 4.142 |
| Change | - | 3.4% | -84.43% | -26.55% | 3.58% | 56.21% |
| Enterprise Value (EV) 1 | 11.01 | -6.823 | -8.621 | -3.05 | 0.4389 | -6.568 |
| Change | - | -161.96% | -26.35% | 64.62% | 114.39% | -1,596.36% |
| P/E | - | - | - | - | - | -0.06x |
| PBR | - | 0.58x | - | - | - | 0.7x |
| PEG | - | - | - | - | - | - |
| Capitalization / Revenue | 4.14x | 12.2x | - | - | - | - |
| EV / Revenue | 2.1x | -3.71x | - | - | - | - |
| EV / EBITDA | -1.42x | 0.53x | 0.38x | 0.24x | -0.08x | 1.61x |
| EV / EBIT | -1.41x | 0.53x | 0.38x | 0.24x | -0.08x | 1.6x |
| EV / FCF | -1.26x | 1.76x | 0.6x | 0.34x | -0.15x | -3.6x |
| FCF Yield | -79.6% | 57% | 167% | 295% | -674% | -27.7% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | - | - | - | - | - | -129.1 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 5.233 | 1.84 | - | - | - | - |
| EBITDA 1 | -7.768 | -12.79 | -22.97 | -12.88 | -5.73 | -4.089 |
| EBIT 1 | -7.786 | -12.81 | -22.98 | -12.89 | -5.734 | -4.096 |
| Net income 1 | -7.352 | -12.77 | -31.61 | -12.54 | -5.576 | -12.52 |
| Net Debt 1 | -10.64 | -29.21 | -12.11 | -5.61 | -2.213 | -10.71 |
| Reference price 2 | 32,759.974 | 17,841.586 | 2,203.200 | 936.000 | 331.200 | 7.786 |
| Nbr of stocks (in thousands) | 0.66 | 1.26 | 1.58 | 2.74 | 8.01 | 532 |
| Announcement Date | 3/18/21 | 3/25/22 | 3/27/23 | 3/22/24 | 3/21/25 | 3/31/26 |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 21.1x | 7.39x | 15.06x | 1.37% | 70.51B | |
| 30.8x | 7.85x | 23.9x | 0.05% | 54.05B | |
| -86.72x | 15.69x | -80x | -.--% | 28.95B | |
| 30.53x | 5.98x | 15.83x | -.--% | 24.05B | |
| -14.6x | 5.15x | -6.72x | -.--% | 23.31B | |
| 56.06x | 22.95x | 59.1x | 0.07% | 18.67B | |
| 25.16x | 4.78x | 16.02x | -.--% | 18.37B | |
| -1224.8x | 38.15x | -15183.55x | -.--% | 16.1B | |
| 15.92x | 4.69x | 10.95x | -.--% | 12.72B | |
| Average | -127.39x | 12.51x | -1,681.05x | 0.16% | 29.64B | |
| Weighted average by Cap. | -63.63x | 10.70x | -909.74x | 0.38% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- DCOY Stock
- FP11 Stock
- Valuation Decoy Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
